Agios licenses exclusive global rights from Oscotec to SYK inhibitor cevidoplenib in deal with USD 25 million upfront payment
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. AGIO | 0.00 |
- Agios signed an exclusive global license deal with Oscotec for cevidoplenib, a late-stage oral SYK inhibitor.
- Deal adds an immune thrombocytopenia program; Agios targets up to USD 1 billion in peak U.S. sales potential.
- Oscotec gets USD 25 million upfront; eligible for up to USD 140 million in development and regulatory milestones.
- Agreement includes commercial milestones; tiered royalties from high single digits to mid-teens on net sales.
- Oscotec can seek exclusive South Korea rights after Phase 3 results; Agios plans Phase 3 start in H1 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010500PRIMZONEFULLFEED9729374) on June 01, 2026, and is solely responsible for the information contained therein.